Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Professor Miguel Quinones-Mateu

PositionWebster Family Chair in Viral Pathogenesis
DepartmentDepartment of Microbiology and Immunology
Research summaryHIV, RNA viruses, viral evolution, drug resistance, drug discovery, metagenomics, novel methodologies

Research

I hold the Webster Family Chair in Viral Pathogenesis. My research group is interested in (i) understanding the mechanisms and clinical consequences of drug resistant viruses, such as transmission and pathogenicity studies, using a series of tools, including next generation (deep) sequencing technology and (ii) studying latently HIV-infected cells aimed to evaluate novel strategies -drug discovery- to eradicate HIV infection.

Publications

Silver, N., Paynter, M., McAllister, G., Atchley, M., Sayir, C., Short, J., … Quiñones‑Mateu, M. E. (2018). Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Research & Therapy, 15, 18. doi: 10.1186/s12981-018-0206-y

Ndashimye, E., Avino, M., Kyeyune, F., Nankya, I., Gibson, R. M., Nabulime, E., … Quiñones‑Mateu, M. E., & Arts, E. J. (2018). Absence of HIV-1 drug resistance mutations supports the use of Dolutegravir in Uganda. AIDS Research & Human Retroviruses, 34(5), 404-414. doi: 10.1089/aid.2017.0205

Tomas, M. E., Mana, T. S. C., Wilson, B. M., Nerandzic, M. M., Joussef-Piña, S., Quiñones‑Mateu, M. E., & Donskey, C. J. (2018). Tapering courses of oral vancomycin induce persistent disruption of the microbiota that provide colonization resistance to clostridium difficile and vancomycin-resistant enterococci in mice. Antimicrobial Agents & Chemotherapy, 62(5), e02237-17. doi: 10.1128/AAC.02237-17

Yendewa, G. A., Poveda, E., Yendewa, S. A., Sahr, F., Quiñones‑Mateu, M. E., & Salata, R. A. (2018). HIV/AIDS in Sierra Leone: Characterizing the hidden epidemic. AIDS Reviews, 20(2), 104-113. doi: 10.24875/AIDSRev.M18000022

Weber, J., Gibson, R. M., Sácká, L., Strunin, D., Hodek, J., Weberová, J., … Quiñones‑Mateu, M. E. (2017). Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Research & Therapy, 14(1), 15. doi: 10.1186/s12981-017-0144-0

Chapter in Book - Research

Quiñones‑Mateu, M. E., Moore-Dudley, D. M., Jegede, O., Weber, J., & Arts, E. J. (2008). Viral drug resistance and fitness. In K.-T. Jeang (Ed.), Advances in pharmacology [Vol. 56: HIV-1: Molecular Biology and Pathogenesis]. (pp. 257-296). London, UK: Academic Press. doi: 10.1016/S1054-3589(07)56009-6

Quiñones‑Mateu, M. E., & Arts, E. J. (2006). Virus fitness: Concept, quantification, and application to HIV population dynamics. In E. Domingo (Ed.), Current topics in microbiology and immunology (Vol.299: Quasispecies: Concepts and implications for virology). (pp. 83-140). Berlin, Germany: Springer.

Abraha, A., Troyer, R. M., Quiñones‑Mateu, M. E., & Arts, E. J. (2005). Methods to determine HIV-1 ex vivo fitness. In T. Zhu (Ed.), Methods in molecular biology (Vol. 304: Human retrovirus protocols). Totowa, New Jersey: Humana Press. doi: 10.1385/1-59259-907-9:355

^ Top of page

Journal - Research Article

Silver, N., Paynter, M., McAllister, G., Atchley, M., Sayir, C., Short, J., … Quiñones‑Mateu, M. E. (2018). Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Research & Therapy, 15, 18. doi: 10.1186/s12981-018-0206-y

Tomas, M. E., Mana, T. S. C., Wilson, B. M., Nerandzic, M. M., Joussef-Piña, S., Quiñones‑Mateu, M. E., & Donskey, C. J. (2018). Tapering courses of oral vancomycin induce persistent disruption of the microbiota that provide colonization resistance to clostridium difficile and vancomycin-resistant enterococci in mice. Antimicrobial Agents & Chemotherapy, 62(5), e02237-17. doi: 10.1128/AAC.02237-17

Ndashimye, E., Avino, M., Kyeyune, F., Nankya, I., Gibson, R. M., Nabulime, E., … Quiñones‑Mateu, M. E., & Arts, E. J. (2018). Absence of HIV-1 drug resistance mutations supports the use of Dolutegravir in Uganda. AIDS Research & Human Retroviruses, 34(5), 404-414. doi: 10.1089/aid.2017.0205

Weber, J., Gibson, R. M., Sácká, L., Strunin, D., Hodek, J., Weberová, J., … Quiñones‑Mateu, M. E. (2017). Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Research & Therapy, 14(1), 15. doi: 10.1186/s12981-017-0144-0

Orrú, C. D., Yuan, J., Appleby, B. S., Li, B., Li, Y., Winner, D., … Quiñones‑Mateu, M. E., … Zou, W.-Q. (2017). Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Science Translational Medicine, 9(417), eaam7785. doi: 10.1126/scitranslmed.aam7785

Aralaguppe, S. G., Winner, D., Singh, K., Sarafianos, S. G., Quiñones‑Mateu, M. E., Sönnerborg, A., & Neogi, U. (2017). Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa. Journal of Medical Virology, 89(1), 106-111. doi: 10.1002/jmv.24610

Gibson, R. M., Nickel, G., Crawford, M., Kyeyune, F., Venner, C., Nankya, I., … Quiñones‑Mateu, M. E., & Arts, E. J. (2017). Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries. Infectious Diseases of Poverty, 6, 163. doi: 10.1186/s40249-017-0377-0

Brenner, B. G., Ibanescu, R.-I., Oliveira, M., Roger, M., Hardy, I., Routy, J.-P., … Quiñones‑Mateu, M. E., … on behalf of the Montreal PHI Cohort Study Group. (2017). HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. Journal of Antimicrobial Chemotherapy, 72(8), 2171-2183. doi: 10.1093/jac/dkx118

Li, Q., Karim, A. F., Ding, X., Das, B., Dobrowolski, C., Gibson, R. M., Quiñones‑Mateu, M. E., … Rojas, R. E. (2016). Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis. Scientific Reports, 6, 27566. doi: 10.1038/srep27566

Virk, S. M., Gibson, R. M., Quinones‑Mateu, M. E., & Barnholtz-Sloan, J. S. (2015). Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. PLoS ONE, 10(5), e0124178. doi: 10.1371/journal.pone.0124178

Rodríguez, A. K., Garzaro, D. J., Loureiro, C. L., Gutiérrez, C. R., Ameli, G., Jaspe, R. C., … Quiñones‑Mateu, M. E., … Rangel, H. R. (2014). HIV-1 and GBV-C co-infection in Venezuela. Journal of Infection in Developing Countries, 8(7), 863-868. doi: 10.3855/jidc.3830

Gibson, R. M., Weber, J., Winner, D., Miller, M. D., & Quiñones‑Mateu, M. E. (2014). Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy. PLoS ONE, 9(8), e104512. doi: 10.1371/journal.pone.0104512

Gibson, R. M., Meyer, A. M., Winner, D., Archer, J., Feyertag, F., Ruiz-Mateos, E., … Quiñones‑Mateu, M. E. (2014). Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrobial Agents & Chemotherapy, 58(4), 2167-2185. doi: 10.1128/AAC.02710-13

Weber, J., Rose, J. D., Vazquez, A. C., Winner, D., Margot, N., McColl, D. J., … Quiñones‑Mateu, M. E. (2013). Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors. PLoS ONE, 8(6), e65631. doi: 10.1371/journal.pone.0065631

Weber, J., Vazquez, A. C., Winner, D., Gibson, R. M., Rhea, A. M., Rose, J. D., … Quiñones‑Mateu, M. E. (2013). Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism. Journal of Clinical Microbiology, 51(5), 1517-1527. doi: 10.1128/JCM.00092-13

Archer, J., Weber, J., Henry, K., Winner, D., Gibson, R., Lee, L., … Quiñones‑Mateu, M. E. (2012). Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS ONE, 7(11), e49602. doi: 10.1371/journal.pone.0049602

Tebit, D. M., Ndembi, N., Weinberg, A., & Quiñones‑Mateu, M. E. (2012). Mucosal transmission of human immunodeficiency virus. Current HIV Research, 10(1), 3-8. doi: 10.2174/157016212799304689

Jegede, O., Khodyakova, A., Chernov, M., Weber, J., Menéndez-Arias, L., Gudkov, A., & Quiñones‑Mateu, M. E. (2011). Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. Antiviral Research, 91(2), 94-98. doi: 10.1016/j.antiviral.2011.05.004

Selhorst, P., Vazquez, A. C., Terrazas-Aranda, K., Michiels, J., Vereecken, K., Heyndrickx, L., … Quiñones‑Mateu, M. E., … Vanham, G. (2011). Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrobial Agents & Chemotherapy, 55(4), 1403-1413. doi: 10.1128/AAC.01426-10

Weber, J., Vazquez, A. C., Winner, D., Rose, J. D., Wylie, D., Rhea, A. M., … Quiñones‑Mateu, M. E. (2011). Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: A useful tool in the multitarget era of antiretroviral therapy. Antimicrobial Agents & Chemotherapy, 55(8), 3729-3742. doi: 10.1128/AAC.00396-11

Covens, K., Dekeersmaeker, N., Schrooten, Y., Weber, J., Schols, D., Quiñones‑Mateu, M. E., … Van Laethem, K. (2009). Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs. Journal of Clinical Microbiology, 47(7), 2232-2242. doi: 10.1128/JCM.01739-08

Zimmer, J.-M., Roman, F., Lambert, C., Jonckheer, A., Vazquez, A., Plesséria, J.-M., … Quinones‑Mateu, M. E., & De Maeyer, M. (2008). Impact on replicative fitness of the G48E substitution in the protease of HIV-1: An in vitro and in silico evaluation. Journal of Acquired Immune Deficiency Syndromes, 48(3), 255-262. doi: 10.1097/QAI.0b013e318174dca6

Zapata, W., Rodriguez, B., Weber, J., Estrada, H., Quinones‑Mateu, M. E., Zimmerman, P. A., … Rugeles, M. T. (2008). Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. Current HIV Research, 6(6), 531-538. doi: 10.2174/157016208786501463

Xu, W., Zheng, S., Goggans, T. M., Kiser, P., Quinones‑Mateu, M. E., Janocha, A. J., … Erzurum, S. C. (2006). Cystic fibrosis and normal human airway epithelial cell response to influenza A viral infection. Journal of Interferon & Cytokine Research, 26(9), 609-627. doi: 10.1089/jir.2006.26.609

Weber, J., Weberova, J., Carobene, M., Mirza, M., Martinez-Micado, J., Kazanjian, P., & Quiñones‑Mateu, M. E. (2006). Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. Journal of Virological Methods, 136(1-2), 102-117. doi: 10.1016/j.jviromet.2006.04.004

Chen, R., Quinones‑Mateu, M. E., & Mansky, L. M. (2005). HIV-1 mutagenesis during antiretroviral therapy: implications for successful drug treatment. Frontiers in Bioscience, 10, 743-750. doi: 10.2741/1568

Ariën, K. K., Abraha, A., Quiñones‑Mateu, M. E., Kestens, L., Vanham, G., & Arts, E. J. (2005). The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. Journal of Virology, 79(14), 8979-8990. doi: 10.1128/JVI.79.14.8979-8990.2005

Weber, J., Chakraborty, B., Weberova, J., Miller, M. D., & Quiñones‑Mateu, M. E. (2005). Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. Journal of Clinical Microbiology, 43(3), 1395-1400. doi: 10.1128/JCM.43.3.1395-1400.2005

Tapia, N., Fernàndez, G., Parera, M., Gómez-Mariano, G., Clotet, B., Quiñones‑Mateu, M., … Martínez, M. A. (2005). Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology, 338(1), 1-8. doi: 10.1016/j.virol.2005.05.008

Chen, R., Quinones‑Mateu, M. E., & Mansky, L. M. (2004). Drug resistance, virus fitness and HIV-1 mutagenesis. Current Pharmaceutical Design, 10(32), 4065-4070. doi: 10.2174/1381612043382404

Chakraborty, B., Valer, L., De Mendoza, C., Soriano, V., & Quiñones‑Mateu, M. E. (2004). Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Research & Human Retroviruses, 20(9), 1026-1031. doi: 10.1089/aid.2004.20.1026

Ball, S. C., Abraha, A., Collins, K. R., Marozsan, A. J., Baird, H., Quiñones‑Mateu, M. E., … Arts, E. J. (2003). Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. Journal of Virology, 77(2), 1021-1038. doi: 10.1128/JVI.77.2.1021-1038.2003

Weber, J., Rangel, H. R., Chakraborty, B., Tadele, M., Martinez, M. A., Martinez-Picado, J., … Quiñones‑Mateu, M. E. (2003). A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. Journal of General Virology, 84(8), 2217-2228. doi: 10.1099/vir.0.19123-0

Quiñones‑Mateu, M. E., Lederman, M. M., Feng, Z., Chakraborty, B., Weber, J., Rangel, H. R., … Weinberg, A. (2003). Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication. AIDS, 17(16), F39-F48. doi: 10.1097/00002030-200311070-00001

Weber, J., Rangel, H. R., Chakraborty, B., Marotta, M. L., Valdez, H., Fransen, K., … Quiñones‑Mateu, M. E. (2003). Role of baseline pol genotype in HIV-1 fitness evolution. Journal of Acquired Immune Deficiency Syndromes, 33(4), 448-460. doi: 10.1097/00126334-200308010-00005

Quiñones‑Mateu, M. E., Gao, Y., Ball, S. C., Marozsan, A. J., Abraha, A., & Arts, E. J. (2002). In vitro intersubtype recombinants of human immunodeficiency virus type 1: Comparison to recent and circulating in vivo recombinant forms. Journal of Virology, 76(19), 9600-9613. doi: 10.1128/JVI.76.19.9600-9613.2002

Collins, K. R., Quiñones‑Mateu, M. E., Wu, M., Luzze, H., Johnson, J. L., Hirsch, C., … Arts, E. J. (2002). Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. Journal of Virology, 76(4), 1697-1706. doi: 10.1128/JVI.76.4.1697-1706.2002

Quiñones‑Mateu, M. E., Tadele, M., Parera, M., Mas, A., Weber, J., Rangel, H. R., … Martínez, M. A. (2002). Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. Journal of Virology, 76(20), 10546-10552. doi: 10.1128/JVI.76.20.10546-10552.2002

Quiñones‑Mateu, M. E., Weber, J., Rangel, H. R., & Chakraborty, B. (2001). HIV-1 fitness and antiretroviral drug resistance. AIDS Reviews, 3(4), 223-242.

Menéndez-Arias, L., Abraha, A., Quiñones‑Mateu, M. E., Mas, A., Camarasa, M.-J., & Arts, E. J. (2001). Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O Strains. Journal of Biological Chemistry, 276(29), 27470-27479. doi: 10.1074/jbc.M104342200

Marozsan, A. J., Torre, V. S., Johnson, M., Ball, S. C., Cross, J. V., Templeton, D. J., … Quiñones‑Mateu, M. E., … Arts, E. J. (2001). Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. Journal of Virology, 75(18), 8624-8638. doi: 10.1128/JVI.75.18.8624-8638.2001

Torre, V. S., Marozsan, A. J., Albright, J. L., Collins, K. R., Hartley, O., Offord, R. E., Quiñones‑Mateu, M. E., & Arts, E. J. (2000). Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. Journal of Virology, 74(10), 4868-4876. doi: 10.1128/JVI.74.10.4868-4876.2000

García Lerma, J. G., Soriano, V., Mas, A., Quiñones‑Mateu, M. E., Arts, E. J., & Heneine, W. (2000). Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity. Journal of Clinical Microbiology, 38(1), 402-405.

Quiñones‑Mateu, M. E., Ball, S. C., Marozsan, A. J., Torre, V. S., Albright, J. L., Vanham, G., … Arts, E. J. (2000). A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. Journal of Virology, 74(19), 9222-9233. doi: 10.1128/JVI.74.19.9222-9233.2000

Quiñones‑Mateu, M. E., Ball, S. C., & Arts, E. J. (2000). Role of human immunodeficiency virus type 1 group O in the AIDS pandemic. AIDS Reviews, 2(3), 190-202.

Collins, K. R., Mayanja-Kizza, H., Sullivan, B. A., Quiñones‑Mateu, M. E., Toossi, Z., & Arts, E. J. (2000). Greater diversity of HIV-1 quasispecies in HIV-infected individuals with active tuberculosis. Journal of Acquired Immune Deficiency Syndromes, 24(5), 408-417.

Arts, E. J., Quiñones‑Mateu, M. E., Albright, J. L., Marois, J.-P., Hough, C., Gu, Z., & Wainberg, M. A. (1998). 3'-azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. Journal of Virology, 72(6), 4858-4865.

Quiñones‑Mateu, M. E., Mas, A., Lain de Lera, T., Soriano, V., Alcamí, J., Lederman, M. M., & Domingo, E. (1998). LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. Virus Research, 57(1), 11-20. doi: 10.1016/S0168-1702(98)00082-3

Quiñones‑Mateu, M. E., Albright, J. L., Mas, A., Soriano, V., & Arts, E. J. (1998). Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. Journal of Virology, 72(11), 9002-9015.

Quiñones‑Mateu, M. E., Soriano, V., Domingo, E., & Menéndez-Arias, L. (1997). Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology, 236(2), 364-373. doi: 10.1006/viro.1997.8748

Quiñones‑Mateu, M. E., Holguín, A., Dopazo, J., & Nájera, I. (1996). Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env. AIDS Research & Human Retroviruses, 12(12), 1117-1128. doi: 10.1089/aid.1996.12.1117

Patki, A. H., Quiñones‑Mateu, M. E., Dorazio, D., Yen-Lieberman, B., Boom, W. H., Thomas, E. L., & Lederman, M. M. (1996). Activation of antigen-induced lymphocyte proliferation by interleukin- 15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression. Journal of Clinical Investigation, 98(3), 616-621. doi: 10.1172/JCI118831

Quiñones‑Mateu, M. E., Dopazo, J., Esté, J. A., Rota, T. R., & Domingo, E. (1995). Molecular characterization of human immunodeficiency virus type 1 isolates from Venezuela. AIDS Research & Human Retroviruses, 11(5), 605-616. doi: 10.1089/aid.1995.11.605

Nájera, I., Holguín, A., Quiñones‑Mateu, M. E., Muñoz-Fernández, M. A., Nájera, I., López-Galíndez, C., & Domingo, E. (1995). pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology, 69(1), 23-31.

Quiñones‑Mateu, M. E., Finol, H. J., Sucre, L. E., & Torres, S. H. (1994). Muscular changes in Venezuelan wild horses naturally infected with Trypanosoma evansi. Journal of Comparative Pathology, 110(1), 79-89. doi: 10.1016/S0021-9975(08)80272-1

^ Top of page

Journal - Research Other

Yendewa, G. A., Poveda, E., Yendewa, S. A., Sahr, F., Quiñones‑Mateu, M. E., & Salata, R. A. (2018). HIV/AIDS in Sierra Leone: Characterizing the hidden epidemic. AIDS Reviews, 20(2), 104-113. doi: 10.24875/AIDSRev.M18000022

Gibson, R. M., Schmotzer, C. L., & Quiñones‑Mateu, M. E. (2014). Next-generation sequencing to help monitor patients infected with HIV: Ready for clinical use? Current Infectious Disease Reports, 16(4), 401. doi: 10.1007/s11908-014-0401-5

Quiñones‑Mateu, M. E., Avila, S., Reyes-Teran, G., & Martínez, M. A. (2014). Deep sequencing: Becoming a critical tool in clinical virology. Journal of Clinical Virology, 61(1), 9-19. doi: 10.1016/j.jcv.2014.06.013

Quiñones‑Mateu, M. E., & Vanham, G. (2012). HIV microbicides: Where are we now? Current HIV Research, 10(1), 1-2. doi: 10.2174/157016212799304724

Jegede, O., Babu, J., Di Santo, R., McColl, D. J., Weber, J., & Quiñones‑Mateu, M. E. (2008). HIV type 1 integrase inhibitors: From basic research to clinical implications. AIDS Reviews, 10(3), 172-189. [Review].

Weber, J., Piontkivska, H., & Quiñones‑Mateu, M. E. (2006). HIV type 1 tropism and inhibitors of viral entry: Clinical implications. AIDS Reviews, 8(2), 60-77. [Review].

Collins, K. R., Quiñones‑Mateu, M. E., Toossi, Z., & Arts, E. J. (2002). Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Reviews, 4(3), 165-176. [Review].

Esté, J. A., Quiñones‑Mateu, M. E., Marcano, T., & Taibo, M. E. (1993). Seroprevalence of retroviruses in the Amazonian rainforest. AIDS, 7(7), 1025. [Letter].

More publications...